A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Study Summary

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Conditions

Esophageal Squamous Cell Carcinoma High Grade Serous Ovarian Cancer Head and Neck Squamous Cell Carcinoma Colorectal Cancer Castration-resistant Prostate Cancer Non Small Cell Lung Cancer Endometrium Cancer Triple Negative Breast Cancer

Interventions / Drugs

IDE034

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment150 participants

Primary Completion—

Lead SponsorIDEAYA Biosciences

Data Retrieved2026-04-11 04:16:36.812137+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.